Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti MG, Aieta M, Ciccarese M, Pisconti S, Bordonaro R, Russo A, Febbraro A, Schiavone P, Quaranta A, Caliolo C, Loparco D, Cinefra M, Colucci G, Cinieri S; Gruppo Oncologico dell’Italia Meridionale (GOIM). Orlando L, et al. Among authors: caliolo c. Breast. 2024 Apr 5;75:103725. doi: 10.1016/j.breast.2024.103725. Online ahead of print. Breast. 2024. PMID: 38615483 Free PMC article.
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
Orlando L, Lorusso V, Giotta F, Di Maio M, Schiavone P, Fedele P, Quaranta A, Caliolo C, Ciccarese M, Cinefra M, Romito S, Pisconti S, Prete SD, Aieta M, Rizzi D, Maiello E, Colucci G, Cinieri S. Orlando L, et al. Among authors: caliolo c. Breast. 2020 Oct;53:18-22. doi: 10.1016/j.breast.2020.06.002. Epub 2020 Jun 5. Breast. 2020. PMID: 32540553 Free PMC article. Clinical Trial.
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.
Lutrino ES, Orlando L, Febbraro A, Giampaglia M, Zamagni C, Schiavone P, Scavelli C, Dima G, Fedele P, Giordano G, Bilancia D, Quaranta AM, Rubino D, Filippelli G, Fontanella C, Caliolo C, Marino A, Calvani N, Ferrara P, Cinieri S. Lutrino ES, et al. Among authors: caliolo c. Tumori. 2020 Aug;106(4):301-305. doi: 10.1177/0300891619887225. Epub 2019 Dec 18. Tumori. 2020. PMID: 31847742 Free PMC article.
Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.
Marino A, Caliolo C, Sponziello F, Nacci A, Quaranta A, Mazzoni E, Lutrino SE, Rizzo P, Calvani N, Orlando L, Schiavone P, Fedele P, D'Amico M, Chetrì MC, Cinefra M, Ferrara P, Cinieri S. Marino A, et al. Among authors: caliolo c. Tumori. 2015 Sep-Oct;101(5):524-8. doi: 10.5301/tj.5000356. Epub 2015 May 25. Tumori. 2015. PMID: 26045117
BMI variation increases recurrence risk in women with early-stage breast cancer.
Fedele P, Orlando L, Schiavone P, Quaranta A, Lapolla AM, De Pasquale M, Ardizzone A, Bria E, Sperduti I, Calvani N, Marino A, Caliolo C, Mazzoni E, Cinieri S. Fedele P, et al. Among authors: caliolo c. Future Oncol. 2014 Dec;10(15):2459-68. doi: 10.2217/fon.14.180. Future Oncol. 2014. PMID: 25525854
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
Bria E, Furlanetto J, Carbognin L, Brunelli M, Caliolo C, Nortilli R, Massari F, Pedron S, Manfrin E, Pellini F, Bonetti F, Sperduti I, Pollini GP, Scarpa A, Tortora G. Bria E, et al. Among authors: caliolo c. Clin Breast Cancer. 2015 Feb;15(1):16-23. doi: 10.1016/j.clbc.2014.05.004. Epub 2014 Jun 23. Clin Breast Cancer. 2015. PMID: 25034441
13 results